|
1
|
Esposito D, Koliopoulos MG and Rittinger
K: Structural determinants of TRIM protein function. Biochem Soc
Trans. 45:183–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hatakeyama S: TRIM family proteins: Roles
in autophagy, immunity, and carcinogenesis. Trends Biochem Sci.
42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nabeshima K, Inoue T, Shimao Y and
Sameshima T: Matrix metalloproteinases in tumor invasion: Role for
cell migration. Pathol Int. 52:255–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scheau C, Badarau IA, Costache R, Caruntu
C, Mihai GL, Didilescu AC, Constantin C and Neagu M: The role of
matrix metalloproteinases in the epithelial-mesenchymal transition
of hepatocellular carcinoma. Anal Cell Pathol (Amst).
94:239072019.
|
|
6
|
Yanqing L, Omid T and Wei G: p53
modifications: Exquisite decorations of the powerful guardian. J
Mol Cell Biol. 11:564–577. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malkin D: Li-fraumeni syndrome. Genes
Cancer. 2:475–484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guha T and Malkin D: Inherited TP53
mutations and the Li-Fraumeni syndrome. Cold Spring Harb Perspect
Med. 7:a0261872017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Freddie B, Jacques F, Isabelle S, Rebecca
SL, Lindey TA and Ahmedin J: Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jackie Oh S, Han S, Lee W and Lockhart AC:
Emerging immunotherapy for the treatment of esophageal cancer.
Expert Opin Investig Drugs. 25:667–677. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang F, Wang Y, Wang ZQ, Sun P, Wang DS,
Jiang YX, Zhang DS, Wang FH, Xu RH and Li YH: Efficacy and safety
of cisplatin-based versus nedaplatin-based regimens for the
treatment of metastatic/recurrent and advanced esophageal squamous
cell carcinoma: A systematic review and meta-analysis. Dis
Esophagus. 30:1–8. 2017. View Article : Google Scholar
|
|
12
|
Tan P, Ye Y, He L, Xie J, Jing J, Ma G,
Pan H, Han L, Han W and Zhou Y: TRIM59 promotes breast cancer
motility by suppressing p62-selective autophagic degradation of
PDCD10. PLoS Biol. 16:e30000512018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z and Li C, Li Y, Guo X, Yan Z, Gao F
and Li C: DpdtbA-induced growth inhibition in human esophageal
cancer cells involved inactivation of the p53/EGFR/AKT pathway.
Oxid Med Cell Longev. 2019:54146702019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valletti A, Marzano F, Pesole G, Sbisa E
and Tullo A: Targeting chemoresistant tumors: Could trim
proteins-p53 axis be a possible answer? Int J Mol Sci. 20:17762019.
View Article : Google Scholar
|
|
15
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rustgi A and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 372:1472–1473. 2015.PubMed/NCBI
|
|
17
|
Hao L, Du B and Xi X: TRIM59 is a novel
potential prognostic biomarker in patients with non-small cell lung
cancer: A research based on bioinformatics analysis. Oncol Lett.
14:2153–2164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui Z, Liu Z, Zeng J, Zhang S, Chen L,
Zhang G, Xu W, Song L and Guo X: TRIM59 promotes gefitinib
resistance in EGFR mutant lung adenocarcinoma cells. Life Sci.
224:23–32. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo D, Wang Y, Huan X, Huang C, Yang C,
Fan H, Xu Z and Yang L: Identification of a synonymous variant in
TRIM59 gene for gastric cancer risk in a Chinese population.
Oncotarget. 8:11507–11516. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin WY, Wang H, Song X, Zhang SX, Zhou PS,
Sun JM and Li JS: Knockdown of tripartite motif 59 (TRIM59)
inhibits tumor growth in prostate cancer. Eur Rev Med Pharmacol
Sci. 20:4864–4873. 2016.PubMed/NCBI
|
|
21
|
Zhang Y and Yang W: Down-regulation of
tripartite motif protein 59 inhibits proliferation, migration and
invasion in breast cancer cells. Biomed Pharmacother. 89:462–467.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan P, He L and Zhou Y: TRIM59 deficiency
curtails breast cancer metastasis through SQSTM1-selective
autophagic degradation of PDCD10. Autophagy. 15:747–749. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu W, Chen J, Wu J, Lin J, Yang S and Yu
H: Knockdown of tripartite motif-59 inhibits the malignant
processes in human colorectal cancer cells. Oncol Rep.
38:2480–2488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen H, Zhang J, Zhang Y, Feng Q, Wang H,
Li G, Jiang W and Li X: Knockdown of tripartite motif 59 (TRIM59)
inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR
signalling pathway. Gene. 698:50–60. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aierken G, Seyiti A, Alifu M and Kuerban
G: Knockdown of tripartite-59 (trim59) inhibits cellular
proliferation and migration in human cervical cancer cells. Oncol
Res. 25:381–388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen G, Chen W, Ye M, Tan W and Jia B:
TRIM59 knockdown inhibits cell proliferation by down-regulating the
Wnt/β-catenin signaling pathway in neuroblastoma. Biosci Rep.
39:BSR201812772019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu Y, Zhang Z and Xu G: TRIM proteins in
neuroblastoma. Biosci Rep. 39:BSR201920502019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao R, Lv G, Zhang C, Wang X and Chen L:
TRIM59 induces epithelial-to-mesenchymal transition and promotes
migration and invasion by PI3K/AKT signaling pathway in
medulloblastoma. Oncol Lett. 15:8253–8260. 2018.PubMed/NCBI
|
|
29
|
Wang Y, Zhou Z, Wang X, Zhang X, Chen Y,
Bai J and Di W: Trim59 is a novel marker of poor prognosis and
promotes malignant progression of ovarian cancer by inducing
annexin a2 expression. Int J Biol Sci. 14:2073–2082. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang P, Zhang H, Wang Y, Zhang P and Qi
Y: Tripartite motif-containing protein 59 (TRIM59) promotes
epithelial ovarian cancer progression via the focal adhesion
kinase(FAK)/AKT/Matrix metalloproteinase (MMP) pathway. Med Sci
Monit. 25:3366–3373. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khatamianfar V, Valiyeva F, Rennie PS, Lu
W, Yang BB, Bauman G, Moussa M and Xuan JW: TRIM59, a novel
multiple cancer biomarker for immunohistochemical detection of
tumorigenesis. BMJ Open. 2:e0014102012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang XP, Li X, Situ MY, Huang LY, Wang J,
He T, Yan QH, Xie XY, Zhang YJ, Gao YH, et al: Entinostat reverses
cisplatin resistance in esophageal squamous cell carcinoma via
down-regulation of multidrug resistance gene 1. Cancer Lett.
414:294–300. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ilson DH: Esophageal cancer chemotherapy:
Recent advances. Gastrointest Cancer Res. 2:85–92. 2008.PubMed/NCBI
|
